Cancer BiologybioRxivPreprint
Pharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responses
Elias Van De Vijver, Kylian Decroix, Delphine Burggraeve…·Marleen Van Troys
This paper shows that combining LDN57444 with low-dose sorafenib enhances anti-tumor effects in hepatocellular carcinoma by reversing drug-induced adaptive responses.
DOI 10.64898/2026.05.15.725527